Presentation is loading. Please wait.

Presentation is loading. Please wait.

Creating a virtuous cyclepath through the valley of death Professor Warwick Anderson AM CEO, NHMRC.

Similar presentations


Presentation on theme: "Creating a virtuous cyclepath through the valley of death Professor Warwick Anderson AM CEO, NHMRC."— Presentation transcript:

1 Creating a virtuous cyclepath through the valley of death Professor Warwick Anderson AM CEO, NHMRC

2 Research Virtuous Cycle – Focus on innovative industries – 2010-2011, pharmaceutical industry invested approximately $1billion in Research and Development – 2011-2012, pharmaceutical industry earned $4billion in exports

3 NHMRC Strategic Plan 2013-2015 Leadership role in research translation – Continued support of research translation through funding schemes Centres of Research Excellence Partnership Centres for Better Health Practitioner Fellowships Development Grants – Research Translation Faculty

4 Research Translation Faculty – Newly established Faculty with more than 2,500 NHMRC funded researchers – Identify the major evidence - practice gaps in NHMRC’s “Major Health Issues”, and – Develop a “Case for Action”, on how NHMRC can address the gap Advice to government Clinical or public health guidelines Transformative research through a Targeted Call for Research.

5 Development Grants – Support research at the early proof-of-principle or pre-seed stage – Since 2003: 855 applications received 206 projects funded worth approximately $53 million Year Expenditure on Development Grants

6 Development Grants – Grants are becoming increasingly competitive 2006: 32.4% successful, 2011: 16.3% successful Administering Institution# of apps# of grantsfunded rate Grand Total855206 24.1% University of Queensland832428.9% Monash University691724.6% University of Western Australia661624.2% University of Melbourne641523.4% Baker IDI Heart and Diabetes Institute251248.0% University of Adelaide491224.5% University of Sydney631117.5% Walter and Eliza Hall Institute311135.5% University of Wollongong21942.9% Queensland University of Technology21733.3% University of New South Wales40717.5% Australian National University22627.3% Macfarlane Burnet Institute for Medical Research and Public Health18633.3% Murdoch Children's Research Institute20630.0% Garvan Institute of Medical Research16425.0% Ludwig Institute for Cancer Research44100.0% University of South Australia14428.6% Centre for Eye Research Australia Ltd6350.0% La Trobe University12325.0% Queensland Institute of Medical Research17317.6% Royal Melbourne Institute of Technology13323.1% Swinburne University of Technology7342.9% Bionic Ear Institute3266.7% Flinders University2627.7% Royal North Shore Hospital22100.0% Aggregate Applications 2003 to 2012

7 Development Grant success stories – Professor Timothy St Pierre University of Western Australia 2002-2004: $341,210 Non-invasive measurement and imaging of hepatic iron concentrations using nuclear magnetic resonance Launch of FerriScan in 2004 – Professor Ted Maddess Australian National University 2006: $113,487 Wireless objective visual field testing for glaucoma diagnosis Product went to market in 2010

8 Development Grant success stories – Professor Zee Upton Queensland University of Technology 2005-2006: $156,871 Pre-clinical evaluation and optimisation of a novel therapy for burns Sales commence in Europe in 2012 – Professor Sarah Robertson University of Adelaide 2002-2005: $481,980 GM-CSF regulation of pre-implantation embryo development Product went to market in 2011

9 Nature (2008) 453:840-842 The Valley of Death – Not all of the research from the 206 Development Grants will make it across the bridge – How to improve the safety of the bridge across the Valley of Death?

10 ACIG Evaluation of Development Grants Scheme – Commissioned an independent assessment of the economic, health and industry outcomes from the NHMRC investment in the Development Grants scheme – 40 completed grants surveyed: 85% reached complete or partial proof of concept at grant completion 80% secured a commercial partner 55% are currently under some form of commercial development 6 have resulted in a product to market or awaiting regulatory approval

11 ACIG Evaluation of Development Grants Scheme – Recommendations: Scheme design to be retained unless there are other reasons for restructure Greater consultation with investors and industry on incorporation of commercial milestones in grant reporting Consultation with Commercialisation Australia and other appropriate agencies Develop and publicise successful case studies

12 Other considerations: – NHMRC Medical Research Endowment Account – Intellectual Property Review – Clinical Trials – Strategic Review of Health and Medical Research (McKeon Review) – “Fiscal Rectitude” – Australia in the Asian Century White Paper

13 NHMRC Medical Research Endowment Account – Purpose of the account is to provide assistance: To foster medical research and training and public health research and training throughout Australia National Health and Medical Research Council Act 1992

14 Intellectual Property Review Report on Collaborations between the Public and Private Sectors: The Role of Intellectual Property, September 2012 – Recommended: » Adjusting key performance indicators for publicly funded research organisations (PFROs) to give greater incentives for industry collaboration » Increase project management skills in PFROs » Helping small business to better engage with public researchers » De-risking early stage intellectual property

15 Clinical Trials – Essential component of the research translation process – Australia facing increasing competition from: Developing economies in our region Developed economies due to the high value of the $AUD – Clinical Trials Action Group Recommendations provide the roadmap to build clinical trial activity in Australia

16 Clinical Trials – NHMRC launched the clinical trials website in October http://www.australianclinicaltrials.gov.au/ – NHMRC will establish a working group to develop the interactive web portal – Standing Council on Health agreed that a national approach to ethical review and approval of clinical trials will be implemented by June 2013 NHMRC has developed documents and guidance material to support this transition and been actively involved

17 Strategic Review of Health and Medical Research (McKeon Review) – NHMRC submission http://www.nhmrc.gov.au/_files_nhmrc/file/research/nhmr c_submission_mckeon_120417.pdf – Draft recommendations: Enhancing the commercial pathway to impact, through increased funding of early stage product development Facilitating the exchange between research and industry and improve access to scale commercialisation services

18 Fiscal Rectitude – Dr Martin Parkinson, Treasury Secretary Nation’s taxation base is weaker than forecast in the mid- 2000s Commonwealth tax receipts are expected to remain approximately $20 billion per annum lower than pre-GFC projections – Closing this gap would require governments to raise more revenue and achieve significant savings » “The public will need to make thoughtful decisions about what it wants government to provide, and how it expects these things will be provided”.

19 Australia in the Asian Century White Paper – Health and medical research sector has been missed – NHMRC has been developing links with the Asia-Pacific region Global Health – GACD call for research on hypertension prevention in low to middle income countries – Is a strategic priority area in the Project Grant Scheme – Previous tripartite with NZHRC and Wellcome Trust Collaboration with A*STAR Forum on H5N1 pandemic preparedness

20 What will the cyclepath through the Valley of Death look like?


Download ppt "Creating a virtuous cyclepath through the valley of death Professor Warwick Anderson AM CEO, NHMRC."

Similar presentations


Ads by Google